Abstract | PURPOSE: There is no standard second-line treatment for patients with unresectable advanced or recurrent gastric cancer (URGC) in the event that first-line treatment fails. Moreover, the benefits of second-line chemotherapy in elderly patients remain uncertain. The aim of this study was to identify the benefits of the second-line paclitaxel (PTX) plus doxifluridine (5'-DFUR) regimen for URGC in elderly patients in comparison to nonelderly patients. METHODS: We retrospectively examined the clinical outcomes of the second-line PTX plus 5'-DFUR regimen in patients with URGC, who had previously been treated with S-1-based first-line chemotherapy. RESULTS: A total of 27 patients (10 elderly, ≥70 years old; 17 nonelderly, <70 years old) were enrolled in the study. The clinical benefit rate (complete response, partial response, and stable disease) in the elderly group was 6 of 10 (60%), and that of the nonelderly group was 9 of 17 (53%). Age had no statistically significant influence on the response rate, and no grade 4 adverse events were observed in either group. In addition, the median survival time was 12.2 months in both groups. CONCLUSION: Although it remains unclear whether second-line chemotherapy contributes to survival in patients with URGC, the combination of PTX plus 5'-DFUR might be the treatment of choice for second-line chemotherapy in both elderly and nonelderly patients who have already received an S-1-based first-line treatment.
|
Authors | Tomomi Yakabe, Hirokazu Noshiro, Osamu Ikeda, Atsushi Miyoshi, Yoshihiko Kitajima, Seiji Satoh |
Journal | Journal of cancer research and clinical oncology
(J Cancer Res Clin Oncol)
Vol. 137
Issue 10
Pg. 1499-504
(Oct 2011)
ISSN: 1432-1335 [Electronic] Germany |
PMID | 21830159
(Publication Type: Journal Article)
|
Chemical References |
- Drug Combinations
- Floxuridine
- S 1 (combination)
- Tegafur
- Oxonic Acid
- Paclitaxel
- doxifluridine
|
Topics |
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Drug Combinations
- Female
- Floxuridine
(administration & dosage)
- Humans
- Male
- Neoplasm Recurrence, Local
(drug therapy)
- Oxonic Acid
(therapeutic use)
- Paclitaxel
(administration & dosage)
- Retrospective Studies
- Stomach Neoplasms
(drug therapy, mortality)
- Tegafur
(therapeutic use)
|